Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days).
BACKGROUND
Current guidelines on the management of urinary tract infection recommend treating febrile urinary tract infection or acute pyelonephritis with antimicrobials for at least 14 days. Few randomized trials showed the effectiveness of treatment durations of 5 to 7 days but this has only been studied in young previously healthy women.


METHODS
A randomized placebo-controlled double-blind multicenter non-inferiority trial in which 400 patients with community acquired febrile urinary tract infection will be randomly allocated to a short treatment arm (7 days of ciprofloxacin or 7 days of empirical beta-lactams +/- gentamicin intravenously with early switch to oral ciprofloxacin followed by 7 days of blinded placebo) or standard treatment arm (7 days of ciprofloxacin or 7 days of empirical beta-lactams +/- gentamicin intravenously with early switch to oral ciprofloxacin followed by 7 days of blinded ciprofloxacin). The study is performed in the Leiden region in which one university hospital, 6 general hospitals and 32 primary health care centers are clustered. Patients eligible for randomization are competent patients aged 18 years or above with a presumptive diagnosis of acute pyelonephritis as defined by the combination of fever, one or more symptoms of urinary tract infection and a positive urine nitrate test and/or the presence of leucocyturia. Exclusion criteria are known allergy to fluoroquinolones, female patients who are pregnant or lactating, polycystic kidney disease, permanent renal replacement therapy, kidney transplantation, isolation of ciprofloxacin-resistant causal uropathogen, renal abscess, underlying chronic bacterial prostatitis, metastatic infectious foci and inability to obtain follow-up. The primary endpoint is the clinical cure rate through the 10- to 18-day post-treatment visit. Secondary endpoints are the microbiological cure rate 10- to 18-day post-treatment, the 30- and 90-day overall mortality rate, the clinical cure rate 70- to 84-day post-treatment, relapse rate of UTI and adverse events or complications during 90 days of follow-up.


CONCLUSIONS
This study aims to demonstrate that 7 days of antimicrobial treatment is non-inferior as compared with 14 days of treatment in patients with febrile urinary tract infection. In addition, it will generate insights into the side-effects of antimicrobial treatment in relation to its duration. The study population will also include men, the elderly and patients with significant co-morbidity. Reflecting daily practice of primary health care and emergency departments, the results of this study can be generalized to other locations.
van Nieuwkoop
Cees
C
Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. c.van_nieuwkoop@lumc.nl
van't Wout
Jan W
JW
Assendelft
Willem J J
WJ
Elzevier
Henk W
HW
Leyten
Eliane M S
EM
Koster
Ted
T
Wattel-Louis
G Hanke
GH
Delfos
Nathalie M
NM
Ablij
Hans C
HC
Kuijper
Ed J
EJ
Pander
Jan
J
Blom
Jeanet W
JW
Spelt
Ida C
IC
van Dissel
Jaap T
JT
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D005334:Fever / Q000188:drug therapy*; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D008297:Male; D014552:Urinary Tract Infections / Q000188:drug therapy*; D047090:beta-Lactams / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D047090:beta-Lactams; D002939:Ciprofloxacin
Eur Urol. 2001 Nov;40(5):576-88
11752870
Int J Antimicrob Agents. 1999 May;11(3-4):189-96; discussion 213-6
10394969
Ann Epidemiol. 2003 Feb;13(2):144-50
12559674
Ann Pharmacother. 2007 Nov;41(11):1859-66
17911203
Am J Emerg Med. 1997 Mar;15(2):148-51
9115515
J Urol. 2004 Feb;171(2 Pt 1):734-9
14713799
Clin Ther. 2002 Feb;24(2):223-36
11911553
Int J Antimicrob Agents. 2004 Mar;23 Suppl 1:S41-53
15037328
Int J Antimicrob Agents. 2008 Feb;31 Suppl 1:S40-5
18023152
JAMA. 2003 Sep 24;290(12):1624-32
14506122
Eur J Clin Microbiol Infect Dis. 1990 May;9(5):317-23
2197091
Ann Intern Med. 1987 Mar;106(3):341-5
3492950
Int J Antimicrob Agents. 2006 Aug;28 Suppl 1:S49-63
16854569
Arch Intern Med. 1999 Jan 11;159(1):53-8
9892331
Stat Med. 2003 Jan 30;22(2):169-86
12520555
Am Fam Physician. 2005 Mar 1;71(5):933-42
15768623
Infect Dis Clin North Am. 2003 Jun;17(2):333-51
12848473
Curr Med Res Opin. 2007 Nov;23(11):2637-45
17880755
Scand J Infect Dis. 2003;35(1):34-9
12685882
Infect Dis Clin North Am. 2003 Jun;17(2):303-32
12848472
Arch Intern Med. 2003 Oct 27;163(19):2393; author reply 2393-4
14581259
Pharmacoeconomics. 2005;23(11):1123-42
16277548
Urology. 2008 Jan;71(1):17-22
18242357
Clin Infect Dis. 2007 Aug 1;45(3):273-80
17599303
N Engl J Med. 2006 Oct 19;355(16):1690-8
17050893
Clin Infect Dis. 1999 Oct;29(4):745-58
10589881
JAMA. 2000 Mar 22-29;283(12):1583-90
10735395
Obstet Gynecol. 2008 Mar;111(3):785-94
18310389
Clin Infect Dis. 1996 Jun;22(6):1051-6
8783709
Clin Infect Dis. 1992 Nov;15 Suppl 1:S216-27
1477233
Curr Med Res Opin. 2007 Jun;23(6):1403-13
17559736
JAMA. 2006 Mar 8;295(10):1152-60
16522836
BMJ. 2008 Nov 11;337:a2390
19001484